AVIR Q3 2022 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$16M

Net Income

-$8M

EPS (Diluted)

$-0.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$687M

Total Liabilities

$23M

Stockholders' Equity

$663M

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$33M	-100.0%
Gross Profit	$0	-$10M	+100.0%
Operating Income	-$16M	-$22M	+26.5%
Net Income	-$8M	-$28M	+71.4%